Next Article in Journal
p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction
Next Article in Special Issue
“Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer
Previous Article in Journal
Cannabidiol (CBD) as a Promising Anti-Cancer Drug
Previous Article in Special Issue
Size-Exclusion Chromatography as a Technique for the Investigation of Novel Extracellular Vesicles in Cancer
Communication

Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer

1
Acobiom, 1682 Rue de la Valsière, 34790 Grabels, France
2
Department of Pathology, Beaujon Hospital-Université de Paris–INSERM U1149, 92110 Clichy, France
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(11), 3204; https://doi.org/10.3390/cancers12113204
Received: 29 September 2020 / Revised: 26 October 2020 / Accepted: 27 October 2020 / Published: 30 October 2020
Pancreatic adenocarcinoma is predicted to be the 2nd cause of death by cancer in Western Countries in 2023. Most patients are diagnosed at an advanced stage for which chemotherapy is the main treatment. In this study we developed through an innovative approach, a simple nine genes blood RNA-based signature that predicts sensitivity to gemcitabine, one of the main regimens in combination with nab-paclitaxel or alone in less fit patients.
Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second cause of cancer death by 2022. For nearly 80% of patients, diagnosis occurs at an advanced, nonsurgical stage, making such patients incurable. Gemcitabine is still an important component in PDAC treatment and is most often used as a backbone to test new targeted therapies and there is, to date, no routine biomarker to predict its efficacy. Samples from a phase III randomized trial were used to develop through a large approach based on blood-based liquid biopsy, transcriptome profiling, and machine learning, a nine gene predictive signature for gemcitabine sensitivity. Patients with a positive test (41.6%) had a significantly longer progression free survival (PFS) (3.8 months vs. 1.9 months p = 0.03) and a longer overall survival (OS) (14.5 months vs. 5.1, p < 0.0001). In multivariate analyses, this signature was independently associated with PFS (HR = 0.5 (0.28–0.9) p = 0.025) and OS (HR = 0.39 (0.21–0.7) p = 0.002). View Full-Text
Keywords: pancreatic cancer; predictive diagnosis; liquid biopsy; gemcitabine pancreatic cancer; predictive diagnosis; liquid biopsy; gemcitabine
Show Figures

Graphical abstract

MDPI and ACS Style

Piquemal, D.; Noguier, F.; Pierrat, F.; Bruno, R.; Cros, J. Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer. Cancers 2020, 12, 3204. https://doi.org/10.3390/cancers12113204

AMA Style

Piquemal D, Noguier F, Pierrat F, Bruno R, Cros J. Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer. Cancers. 2020; 12(11):3204. https://doi.org/10.3390/cancers12113204

Chicago/Turabian Style

Piquemal, David, Florian Noguier, Fabien Pierrat, Roman Bruno, and Jerome Cros. 2020. "Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer" Cancers 12, no. 11: 3204. https://doi.org/10.3390/cancers12113204

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop